Abstract:Objective:In this study, we analyzed the efficacy and tolerability of mycophenolate mofetil and three other immunosuppressants in Graves’ ophthalmopathy (GO) patients. Methods:Fifty four untreated GO patients were enrolled in this study. The diagnosis of GO was based on the presence of the typical clinical features and excluding of the possibility of cranial/orbital diseases, and the severity of ophthalmopathy was at least equal to or more severe than Class 2 in NO SPECS classification. Those who could afford were randomly assigned to receive either mycophenolate mofetil (MMF, n =12, 16～18 mg per kilogram per day) or cyclosporin A (CsA, n =11, 5～6 mg per kilogram of body weight per day) therapy. The others were randomly assigned to be given either prednisone ( n =16, finished in 13 case, 40 mg per day for 4 weeks, 20 mg for 4 weeks, and 10 mg for 4 weeks) or tripterygium multi glycosides (T Ⅱ , n =15, 30～60 mg per day). The disease severity and therapeutic response were quantitatively assessed according to the Ophthalmopathy Index Scoring System from Given wilson (1989) with sensibly modified. The improvement or progression of ophthalmopathy was defined if the variation, either increase or decrease of the score, reached 3 or more in the ophthalmopathy index. If this did not occur, a lack of response was indicated. In patients who had hyperthyroidism, antithyroid drugs were also administered.Results:After 12 week therapy, 7 (54 percent) of the 13 treated with prednisone improved, the remaining 6 (46 percent) lacked response. In T Ⅱ group, 10 (67 percent) of 15 responded to the therapy, 5 (33 percent) had no change. There was no significant difference in clinical response between the above 2 groups ( P 0.05). Five CsA treated and 11 MMF treated patients responded to therapy (45 percent vs 92 percent; P 0.05) . It seems that MMF is more effective than CsA in the treatment of GO although a significant decrease ( P 0.01) in the mean score of the CsA group has also been shown at the end of the course. None of all the 51 patients in the 4 groups had worsening of ophthalmopathy. Among 16 patients in prednisone group, 3 (19 percent) gained body weight by more than 5 percent, 2 (13 percent) developed impaired glucose tolerance (IGT). These two patients and one of the three weight gaining patients ceased the therapy. Impermanent menopause happened in 1 (11 percent) of the females in T Ⅱ group at the sixth month in sequel treatment after the course. Conclusion:MMF may be more effective than CsA in the treatment of Graves’ophthalmopathy. T Ⅱ may have a equal effectiveness and perhaps a better tolerability than prednisone in the immunotherapy of Graves’ ophthalmopathy.

Changes of the mRNA expression of TBX21, GATA3, RORC, FOXP3 before and after the treatment of Graves' hyperthyroidism and Graves' ophthalmopathy

Therapeutic Outcomes of Mycophenolate Mofetil and Three Other Immunosuppressants in Patients with Graves’ Ophthalmopathy

Association Between Intravenous Pulse-Therapy with Immunosuppressant for Graves' Ophthalmopathy and Changes of Peripheral Blood T Cell Subgroup

Immune Effect of Propylthiouracil and Methimazole in the Treatment of Graves' Disease

Changes of Immunoglobulins and CD Series in Patients with Graves' Orbitopathy Treated with High-Dose Methylprednisolone

Differential Microrna Expression in Peripheral Blood Mononuclear Cells from Graves' Disease Patients

The Significance of Changes in Thyrotropin Receptor Antibody and Soluble Intercellular Adhesion Molecule-1 Levels in Patients with Thyroid-Associated Ophthalmopathy During Intravenous Methylprednisolone Pulse Treatment

The Preliminary Study on the Imbalance of Th1/Th2 Chemokines in Patients with Graves Disease

Effects of Thyrostatic Treatment on T,B Lymphocytes and Expression of Costimulatory Molecules on Pripheral Blood Lymphocytes of Patients with Graves' Disease

Clinical Efficacy of Combined Rituximab Treatment in a Woman with Severe Graves' Ophthalmopathy.

Effect of Methimazole Therapy on TH1/TH2 Ratio in Patients with Graves' Disease

THERAPEUTIC EFFECTS OF COMBINATION REGIMENS INCLUDING METHIMAZOLE ON GRAVES HYPERTHYROIDISM: A NETWORK META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

The Efficacy of Rituximab Combined with 131I for Ophthalmic Outcomes of Graves' Ophthalmopathy Patients

The expression of OX40 and OX40L in the peripheral blood of Graves disease patients

Effects of Huangbei Pingjia Capsules on Expressions of Bcl-2 and Bax in Mice with Graves’ Disease

The influence of glucose metabolism and its mechanism in patients with thyroid associated ophthalmopathy treated with high-dose glucocorticoid

MiR-363-5p modulates regulatory T cells through STAT4-HSPB1-Notch1 axis and is associated with the immunological abnormality in Graves' disease

Changes of serum FT3, FT4, sTSH, TRAb, TGA and TMA concentrations in Graves' patients treated with 131I and clinical significances

Factors Associated with the Efficacy of Intravenous Methylprednisolone in Moderate-to-severe and Active Thyroid-Associated Ophthalmopathy: A Single-Centre Retrospective Study.

Short and Long-Term Effects of High-Dose Intravenous Methylprednisolone Pulse Therapy on Thyroid-Associated Ophthalmopathy.

The Change of CD4+CD25+Foxp3+regulatory T Cells in Peripheral Blood of Patients with Graves Disease Treated by Iodine-131